In an upcoming Business Booster webinar being held on Aug. 4 at 2 p.m. ET, join Pfizer as they explore strategies to help protect eligible adult patients against pneumococcal disease caused by medically important serotypes. Topics include the burden of pneumococcal disease in adults, the importance of direct protection with Prevnar 20, Prevnar 13 efficacy and effectiveness (including findings from the CAPiTA trial and real-world data), current ACIP adult pneumococcal vaccination recommendations and clinical scenarios, and the critical role health care providers play in improving adult vaccination rates.
Learn more about our other webinar offerings, including our Business Booster webinar archive, here.
NCPA
